Latest Interviews
Showing 1–5 of 5 transcripts.
Clear all filters- a16z19 min
Healthcare Has Left the Building
A structural transformation is dissolving traditional silos between payers, providers, and technology firms to shift care from centralized hospitals to home settings while leveraging mobile diagnostics and AI-driven logistics. Major market entrants are challenging established models through value-based care initiatives and programmed therapies that enable proactive monitoring and personalized treatments like gene editing. This evolution modernizes the medical ecosystem to prioritize patient outcomes and efficiency, though the fundamental human need for care remains the driving force behind these technological accelerations.
- a16z59 min
a16z Podcast | The Science and Business of Innovative Medicines
Jorge Conde, Vijay Pande, Sonal Chokshi, Vas Narasimhan
Novartis transformed its portfolio through a $50 billion restructuring that divested consumer healthcare to prioritize advanced therapies, data science, and proprietary platforms for cell and gene treatments. Under CEO Vas Narasimhan, the company enforces strict "standard of care" mandates for project approval, integrates market access early in development, and invested $15 billion to own specialized infrastructure while leveraging AI for financial forecasting and pathology analysis. This strategic pivot targets a 10% clinical success rate by shifting from bespoke drug development to modular platforms and dedicated digital innovation centers, positioning the firm to address undruggable targets and future modalities like xenotransplantation.
- a16z17 min
Programming Medicine
The medical field is undergoing a paradigm shift from chemical synthesis to programming living entities like cells, genes, and microbes as direct therapeutics. Four core imperatives—sensing disease, executing treatments, containing activity to specific sites, and self-terminating after success—are now driving the development of advanced therapies such as CAR-T, CRISPR gene editing, and engineered microbiome treatments. This evolution aims to overcome historical safety barriers and treat the thousands of genetic diseases and cancers affecting a significant portion of the global population.
- a16z8 min
Consolidation in Healthcare: What to Make of It?
Jorge Conde, Vijay Pande, Jeffrey Low
Leading healthcare entities are pursuing divergent consolidation strategies, exemplified by Walmart's potential acquisition of Humana to create a vertically integrated retail-insurance model, while Amazon, Berkshire Hathaway, and JPMorgan develop a dispersed employer consortium. Analysts predict that local integration offers more immediate cost reductions than geographically scattered employer alliances, prompting new market entrants to build proprietary pharmacy benefit management capabilities and specialized logistics for complex gene and cell therapies. This sector-wide shift toward vertical monoliths and advanced therapeutic infrastructure is creating entrepreneurial opportunities focused on digital therapeutic reimbursement and friction-free administrative frameworks.
- a16z22 min
Challenges in Healthcare Innovation
The healthcare sector faces a critical efficiency crisis known as Eroom's Law, where rising costs and long timelines for drug discovery are exacerbated by a fundamental lack of biological understanding for complex diseases like Alzheimer's. This challenge is driving a rapid convergence of genomics, artificial intelligence, and engineering, which is transforming medicine from an experimental science into an engineered discipline capable of creating intelligent, logic-based therapies. As the industry shifts from traditional animal models to predictive organ-on-chip systems and embraces digital therapeutics, the alignment of payors, regulators, and innovators is accelerating the delivery of curative precision treatments while extending biological design principles into data storage and manufacturing.